Tonix Pharmaceuticals Analyst Ratings
Tonix Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/01/2023 | 634.28% | Alliance Global Partners | $18 → $8 | Maintains | Buy |
| 06/02/2023 | 1552.13% | Alliance Global Partners | $6.5 → $18 | Maintains | Buy |
| 01/12/2023 | 496.6% | Alliance Global Partners | → $6.5 | Reiterates | → Buy |
| 04/18/2022 | -44.93% | Noble Capital Markets | → $0.6 | Initiates Coverage On | → Outperform |
| 08/31/2021 | 175.36% | Alliance Global Partners | $2 → $3 | Maintains | Buy |
| 08/11/2021 | 83.57% | Alliance Global Partners | $4 → $2 | Maintains | Buy |
| 02/25/2021 | 267.14% | Alliance Global Partners | $3 → $4 | Maintains | Buy |
| 04/18/2019 | — | Roth Capital | Upgrades | Neutral → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 08/01/2023 | 634.28% | 聯盟全球合作伙伴 | 18 美元 → 8 美元 | 維護 | 購買 |
| 06/02/2023 | 1552.13% | 聯盟全球合作伙伴 | 6.5 美元 → 18 美元 | 維護 | 購買 |
| 01/12/2023 | 496.6% | 聯盟全球合作伙伴 | → 6.5 美元 | 重申 | → 購買 |
| 04/18/2022 | -44.93% | 貴族資本市場 | → 0.6 美元 | 啓動覆蓋開啓 | → 跑贏大盤 |
| 08/31/2021 | 175.36% | 聯盟全球合作伙伴 | 2 美元 → 3 美元 | 維護 | 購買 |
| 08/11/2021 | 83.57% | 聯盟全球合作伙伴 | 4 美元 → 2 美元 | 維護 | 購買 |
| 2021 年 2 月 25 日 | 267.14% | 聯盟全球合作伙伴 | 3 美元 → 4 美元 | 維護 | 購買 |
| 04/18/2019 | — | 羅斯資本 | 升級 | 中性 → 買入 |
What is the target price for Tonix Pharmaceuticals (TNXP)?
Tonix Pharmicals（TNXP）的目標價格是多少？
The latest price target for Tonix Pharmaceuticals (NASDAQ: TNXP) was reported by Alliance Global Partners on August 1, 2023. The analyst firm set a price target for $8.00 expecting TNXP to rise to within 12 months (a possible 634.28% upside). 3 analyst firms have reported ratings in the last year.
Alliance Global Partners於2023年8月1日公佈了Tonix Pharmicals（納斯達克股票代碼：TNXP）的最新目標股價。這家分析公司將目標股價定爲8.00美元，預計TNXP將在12個月內升至12個月內（可能上漲634.28％）。去年有3家分析公司公佈了評級。
What is the most recent analyst rating for Tonix Pharmaceuticals (TNXP)?
分析師對Tonix Pharmicals（TNXP）的最新評級是多少？
The latest analyst rating for Tonix Pharmaceuticals (NASDAQ: TNXP) was provided by Alliance Global Partners, and Tonix Pharmaceuticals maintained their buy rating.
Tonix Pharmicals（納斯達克股票代碼：TNXP）的最新分析師評級由Alliance Global Partners提供，Tonix Pharmicals維持買入評
When is the next analyst rating going to be posted or updated for Tonix Pharmaceuticals (TNXP)?
Tonix Pharmicals（TNXP）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Tonix Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Tonix Pharmaceuticals was filed on August 1, 2023 so you should expect the next rating to be made available sometime around August 1, 2024.
分析師在進行了廣泛的研究（包括瀏覽公開財務報表、與Tonix Pharmicals的高管和客戶交談以及聽取業績電話會議）後得出了股票評級。大多數分析師每三個月進行一次評級，因此每家公司每年應該獲得4個評級。Tonix Pharmicals的最新評級是在2023年8月1日提交的，因此您應該預計下一個評級將在2024年8月1日左右公佈。
Is the Analyst Rating Tonix Pharmaceuticals (TNXP) correct?
分析師對Tonix Pharmicals（TNXP）的評級正確嗎？
While ratings are subjective and will change, the latest Tonix Pharmaceuticals (TNXP) rating was a maintained with a price target of $18.00 to $8.00. The current price Tonix Pharmaceuticals (TNXP) is trading at is $1.09, which is out of the analyst's predicted range.
儘管評級是主觀的，將會發生變化，但最新的Tonix Pharmicals（TNXP）評級維持不變，目標股價爲18.00美元至8.00美元。Tonix Pharmicals（TNXP）目前的交易價格爲1.09美元，超出了分析師的預測區間。
譯文內容由第三人軟體翻譯。